AquaLung Therapeutics Corp. Receives NIH Approval to Advance to IND-Enabling Studies Via the STTR Fastrack Phase II Award for Development of A Novel Anti-Inflammatory Therapeutic Antibody for ARDS…

KEY ACTIVITIES & PRESS

May 17

Written By Rebecca Nunn

AquaLung Therapeutics Corp. Receives NIH Approval to Advance to IND-Enabling Studies Via the STTR Fastrack Phase II Award for Development of A Novel Anti-Inflammatory Therapeutic Antibody for ARDS and the Critically Ill

READ PRESS RELEASE

5.20.20

Covid

Rebecca Nunn

Aqualung Therapeutics Corporation Receives A $2.3 Million National Institute Of Health (NIH) Fast-Track Award To Develop A Novel Therapeutic Antibody For Patients With Radiation-Induced Lung Injury

Fight Against COVID 19 May Yield Solutions to ARDS